doi: 10.3389/ftox.2024.1470439, 255
Novo Nordisks semaglutide (Ozempic for diabetes, Wegovy for obesity) and Eli Lillys dual-agonist tirzepatide (Mounjaro, a related drug that also activates the GIP hormone receptor) have become blockbusters , propelling their companies to record-high market valuations ( [15] ) ( [16] )
Dumay J, Moranais M
_ Parlons-en entre humains
These compounds influence collagen production, metabolism, hormone balance, and recovery, making them an exciting option for those looking to improve energy levels, skin health, sleep quality, and muscle maintenance
Semaglutide vs tirzepatide for autoimmune applications Both molecules activate GLP-1 receptors